Endocr Rev 26:688–703PubMedCrossRef 4. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] www.selleckchem.com/products/ABT-737.html Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and
high fracture risk. eFT-508 ic50 J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef 5. Tam CS, Heersche JN, Murray TM, Parsons JA (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506–512PubMedCrossRef 6. Uzawa T, Hori M, Ejiri S, Ozawa H (1995)
Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone. Bone 16:477–484PubMed 7. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. Akt activator J Clin Endocrinol Metab 91:1370–1375PubMedCrossRef 8. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRef 9. Girotra M, Rubin MR, Bilezikian JP (2006) The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7:113–121PubMedCrossRef 10. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513PubMedCrossRef 11. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M (1999) Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on
osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporosis Int Selleck Fludarabine 9:296–306CrossRef 12. Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643–646PubMedCrossRef 13. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94:2915–2921PubMedCrossRef 14. Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH (2004) Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis Rheumatism 50:4028–4034PubMedCrossRef 15. Cosman F, Dawson-Hughes B, Wan X, Krege JH (2012) Changes in vitamin D metabolites during teriparatide treatment.